Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 6Multiple Myeloma 4Kidney Neoplasms 3Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Lymphoma 1Liver Neoplasms 1Leukemia 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Sorafenib 22Bevacizumab 15pembrolizumab 10durvalumab 7Nivolumab 7Ipilimumab 6Drug Therapy 6atezolizumab 5Talaporfin 5spartalizumab 4regorafenib 4lenvatinib 4derazantinib 3Ramucirumab 3Photochemotherapy 3Leucovorin 3Injections 3Fluorouracil 3Doxorubicin 3tremelimumab 2toripalimab 2seocalcitol 2relatlimab 2phosphomannopentaose sulfate 2liposomal doxorubicin 2exatecan 2cabozantinib 2brivanib 2Phototherapy 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liver Neoplasms × perifosine × Clear all
NCT00398814 2014-02-19

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

AEterna Zentaris

Phase 1 Completed
30 enrolled
GastrointestinalGenitourinary

Kidney Neoplasms, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡